Christoforou Nicolas, Gearhart John D
Johns Hopkins Medical Institutions, Institute for Cell Engineering, Baltimore, MD 21205, USA.
Prog Cardiovasc Dis. 2007 May-Jun;49(6):396-413. doi: 10.1016/j.pcad.2007.02.006.
Stem cells are potential agents for the treatment of myocardial infarcts among other heart diseases. Over the past decade, the scientific community has extensively used a wide variety of cells and examined their capacity to both regenerate the infarcted myocardium and improve functionally the diseased hearts. Some of the cells used include skeletal myoblasts, bone marrow-derived cells, adult cardiac resident stem cells, mesenchymal stem cells, and both mouse and human embryonic stem cells (Nat Biotechnol 2005;23:845-856). The reported cardiogenic capacity of the utilitized stem cells is assayed both in vitro through the use of differentiation paradigms and in vivo through transplantation into a variety of animal models of cardiac disease. The purpose of this review article is to summarize recent stem cell applications in cell-based cardiac therapies and their outcomes.
干细胞是治疗心肌梗死及其他心脏病的潜在药物。在过去十年中,科学界广泛使用了各种各样的细胞,并研究了它们再生梗死心肌和改善患病心脏功能的能力。使用的一些细胞包括骨骼肌成肌细胞、骨髓来源的细胞、成年心脏驻留干细胞、间充质干细胞以及小鼠和人类胚胎干细胞(《自然生物技术》2005年;23:845 - 856)。所使用的干细胞的心脏生成能力通过体外使用分化模式以及体内移植到各种心脏病动物模型中进行测定。这篇综述文章的目的是总结基于细胞的心脏治疗中干细胞的最新应用及其结果。